Studies of who receives GLP-1 treatment can reflect different health systems. Researchers used Norwegian registries to describe what diagnoses people had before starting one of five weight-loss medicines [1].
Who was included
The study followed adults aged 18 to 74 who started one of the medicines in 2023 or 2024 (n = 190,818). Researchers matched each to five population controls by age and sex. They checked diagnoses from the prior two years and medicines dispensed in the prior year.
Between 71% and 78% of starters had at least one recorded coexisting condition. Among controls, the range was 49% to 51%. The ranges show variation across the five drug groups [1].
Which conditions were recorded
High blood pressure was recorded in 32% to 38% of starters and 17% to 20% of controls. The corresponding ranges for sleep apnea were 7% to 11% and 2% to 3%.
Trials of GLP-1 treatment for sleep apnea ask a different question about treatment outcomes. This registry study measured diagnoses that preceded treatment.
Opioids and antidepressants were also dispensed more often before treatment in the starter groups. Dispensing records cannot confirm why a drug was prescribed or whether it was taken. The Norwegian results do not establish the health profile of U.S. telehealth patients.